International Flavors & Fragrances
IFF
$84.55
-4.00%
International Flavors & Fragrances Inc. (IFF) is a global leader in specialty ingredients, supplying flavors, fragrances, health and biosciences, and food ingredients to industries including food, beverage, personal care, and pharmaceuticals. As the largest specialty ingredients producer worldwide, IFF distinguishes itself through its proprietary formulations and custom solutions, with its Taste and Scent segments each contributing roughly 25% of profits, while Health & Biosciences leads in probiotics and enzymes. The current investor narrative centers on the company's strategic portfolio reshaping, including the planned divestiture of its Food Ingredients business expected to close in 2027, alongside a recovery in profitability after a challenging period marked by a significant loss in early 2025. Recent attention has been fueled by analyst optimism, with multiple firms reiterating Buy ratings and the stock being highlighted as undervalued with rebound potential.…
IFF
International Flavors & Fragrances
$84.55
Related headlines
Investment Opinion: Should I buy IFF Today?
Based on the analysis, IFF is rated a 'Buy' with a thesis that the stock is undervalued relative to its growth potential and strategic restructuring. The consensus analyst rating is 'Buy' with an average price target of $91.54, implying a 15.6% upside. The stock trades at a price-to-sales ratio of 1.58x, well below the industry average of 6.78x, and a forward PE of 16.5x, which is reasonable for a company expected to grow earnings. The recent quarterly EPS of $0.66 and positive net income of $169 million indicate a turnaround is underway, and the planned divestiture should unlock value.
Sign up to view all
IFF 12-Month Price Forecast
The AI assessment is bullish on IFF, driven by a compelling valuation and improving fundamentals. The stock trades at a significant discount to peers, and the recent earnings recovery suggests the worst may be over. However, the medium confidence reflects the uncertainty around revenue growth and the execution of the divestiture. If the company can sustain its momentum and deliver on its strategic plan, the stock has substantial upside. Key factors to monitor include quarterly revenue trends, margin expansion, and progress on the divestiture. A downgrade to neutral would occur if revenue growth turns negative again or margins fail to improve.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on International Flavors & Fragrances's 12-month outlook, with a consensus price target around $91.54 and implied upside of +8.3% versus the current price.
Average Target
$91.54
0 analysts
Implied Upside
+8.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$71 - $105
Analyst target range
IFF is covered by 18 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.65 (where 1 is Strong Buy and 5 is Sell). The average price target is $91.54, implying an upside of approximately 15.6% from the current price of $79.22. The distribution of ratings is bullish, with no Sell ratings and a majority of Buy or Overweight ratings, as evidenced by recent actions from Morgan Stanley, Argus Research, Citigroup, and Barclays, all maintaining positive stances. The target price range spans from $71.00 (low) to $105.00 (high), with the high target suggesting a potential 32.5% upside, likely reflecting expectations of successful portfolio restructuring and margin expansion. The low target of $71.00 implies a downside of about 10.4%, indicating some uncertainty, but the overall sentiment remains constructive, with analysts seeing the stock as undervalued with significant rebound potential.
Bulls vs Bears: IFF Investment Factors
IFF presents a mixed investment case with compelling valuation and analyst optimism on the bull side, but concerning revenue trends and profitability issues on the bear side. The bull case is currently stronger, supported by a significant discount to peers, a clear strategic plan to divest low-margin businesses, and a recent earnings recovery. However, the key tension lies in whether the company can sustain its revenue growth and margin expansion while managing its debt load. If the turnaround continues and the divestiture proceeds as planned, the stock could re-rate higher; conversely, any stumble in execution could lead to a sharp sell-off given the high expectations.
Bullish
- Undervalued on Sales Basis: IFF trades at a price-to-sales ratio of 1.58x, significantly below the industry average of 6.78x. This substantial discount suggests the market is pricing in the company's recent profitability struggles, but also implies significant upside potential if the turnaround succeeds.
- Strong Analyst Conviction: With 18 analysts covering the stock, the consensus is a 'Buy' with a mean rating of 1.65 (where 1 is Strong Buy). The average price target of $91.54 implies a 15.6% upside from the current price of $79.22, and the high target of $105 suggests a 32.5% potential gain.
- Portfolio Restructuring Catalyst: The planned divestiture of the Food Ingredients business, expected to close in 2027, is a strategic catalyst. This move will streamline operations and focus on higher-margin segments like Taste, Scent, and Health & Biosciences, potentially improving profitability and valuation multiples.
- Recent Profitability Recovery: After a challenging Q1 2025 with a net loss of $1.018 billion, the company has shown a strong recovery. Q1 2026 reported net income of $169 million and EPS of $0.66, indicating a successful turnaround and improved operational efficiency.
Bearish
- Revenue Decline in Q1 2026: Q1 2026 revenue of $2.741 billion declined 3.59% year-over-year, breaking a streak of sequential growth. This deceleration raises concerns about demand softness in key end markets and could signal a broader slowdown.
- Negative Net Margin and EPS: The trailing twelve-month net margin is -3.31%, and EPS is -$0.02, reflecting ongoing profitability challenges. While recent quarters have improved, the company is still not consistently profitable on a TTM basis, which may limit valuation expansion.
- High Debt Levels: With a debt-to-equity ratio of 0.47 and an EV/EBITDA of 29.9x, IFF carries a significant debt burden. High leverage increases financial risk, especially if interest rates remain elevated or cash flows underperform.
- Underperformance vs. S&P 500: Over the past year, IFF returned 11.53% compared to the S&P 500's 18.19%, underperforming by 6.66 percentage points. This relative weakness may persist if the market continues to favor large-cap tech and growth stocks.
IFF Technical Analysis
IFF's price trend over the past year reflects a robust recovery, with the stock up 11.53% over the 1-year period, though it has underperformed the S&P 500's 18.19% gain. The current price of $79.22 sits at approximately 93.8% of its 52-week range (between $59.14 low and $84.45 high), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The 6-month price change of +13.48% and 3-month change of +11.88% confirm a sustained uptrend, with the stock having recovered from a low of $59.14 to approach its 52-week high of $84.45.
Beta
0.94
0.94x market volatility
Max Drawdown
-23.1%
Largest decline past year
52-Week Range
$59-$87
Price range past year
Annual Return
+27.8%
Cumulative gain past year
| Period | IFF Return | S&P 500 |
|---|---|---|
| 1m | +3.3% | +2.8% |
| 3m | +4.3% | +4.2% |
| 6m | +13.0% | +11.3% |
| 1y | +27.8% | +21.5% |
| ytd | +24.3% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IFF Fundamental Analysis
IFF's revenue trajectory has been mixed, with the most recent quarter (Q1 2026) showing revenue of $2.741 billion, a 3.59% decline year-over-year, breaking a streak of sequential growth from $2.589 billion in Q4 2025 to $2.694 billion in Q3 2025. The company's growth has been challenged by softness in certain end markets, but segment data reveals that Taste ($656M) and Scent ($651M) remain the largest contributors, while Health & Biosciences ($595M) and Food Ingredients ($839M) show varying dynamics. The revenue decline in Q1 2026 suggests a deceleration, which is a key concern for investors, though the company's strategic focus on higher-margin segments may support future growth.
Quarterly Revenue
$2.7B
2026-03
Revenue YoY Growth
-3.6%
YoY Comparison
Gross Margin
37.1%
Latest Quarter
Free Cash Flow
$398000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IFF Overvalued?
Given that IFF's trailing twelve-month net income is negative (EPS of -$0.02), the price-to-sales (PS) ratio is the most appropriate valuation metric, as PE ratios are not meaningful for unprofitable companies. The current PS ratio of 1.58x is significantly lower than the industry average of 6.78x (based on historical data), indicating that IFF trades at a substantial discount to its sector peers on a sales basis. This discount is likely justified by the company's recent profitability struggles and negative net margin of -3.31%, but it also suggests potential upside if the company can execute its turnaround plan and improve margins.
PE
-46.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~340x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. IFF's trailing twelve-month net income is negative, with an EPS of -$0.02 and a net margin of -3.31%, indicating that the company is not yet consistently profitable. The debt-to-equity ratio of 0.47 and EV/EBITDA of 29.9x highlight a significant leverage burden, which could strain cash flows if interest rates remain high. Additionally, the recent revenue decline of 3.59% in Q1 2026 suggests potential demand softness, and the company's reliance on a few large segments (Taste and Scent each contribute ~25% of profits) exposes it to sector-specific downturns.
FAQ
Key risks include: (1) Financial risk from high debt (D/E of 0.47) and negative TTM net margin, (2) Market risk from underperformance vs. S&P 500 and high short interest, (3) Competitive risk from larger players and regulatory changes, and (4) Company-specific risk from the divestiture execution and revenue decline. The most severe risk is a failure to improve profitability, which could lead to a drop to the 52-week low of $59.14.
The 12-month forecast is moderately bullish. The base case (50% probability) sees the stock reaching $85-$95, aligning with the analyst average target of $91.54. The bull case (30% probability) targets $95-$105, driven by successful restructuring and growth. The bear case (20% probability) could see the stock fall to $65-$75 if the turnaround stalls. The most likely scenario is the base case, assuming continued recovery and successful divestiture.
IFF is undervalued relative to its industry peers, trading at a PS ratio of 1.58x versus the industry average of 6.78x. On a forward PE basis of 16.5x, it's also reasonable given expected earnings growth. The PEG ratio of 0.18 suggests the market is not fully pricing in growth. However, the discount is justified by the company's recent profitability struggles. If the turnaround succeeds, the stock should re-rate higher.
IFF is a good buy for investors with a higher risk tolerance and a long-term perspective. The stock is undervalued on a sales basis (PS of 1.58x vs. industry 6.78x) and has a consensus 'Buy' rating with a 15.6% upside to the average target. However, the company's recent revenue decline and negative TTM net margin pose risks. If you believe in the turnaround and the divestiture, the risk/reward is favorable, but it's not suitable for conservative investors.
IFF is more suitable for long-term investment (3-5 years) given its turnaround nature and the multi-year divestiture plan. The stock has a beta of 0.944, indicating moderate volatility, and a dividend yield of 2.37%, providing some income. Short-term trading is possible given the volatility, but the fundamental thesis plays out over a longer period. Investors should be prepared for price swings and hold through the restructuring.